Blue Capital Files Securities and Exchange Commission Form 15
HAMILTON, Bermuda, March 30, 2020 (GLOBE NEWSWIRE) — Blue Capital Reinsurance Holdings Ltd. (NYSE:BCRH) (“Blue Capital” or the “Company”) announces […]
AeroCentury Corp. Reports Fourth Quarter 2019 and Fiscal Year 2019 Results
BURLINGAME, Calif., March 30, 2020 (GLOBE NEWSWIRE) — AeroCentury Corp. (“AeroCentury” or the “Company”) (NYSE American: ACY), an independent aircraft […]
TSX News -
MAG SILVER REPORTS 2019 ANNUAL RESULTS
VANCOUVER, British Columbia, March 30, 2020 (GLOBE NEWSWIRE) — MAG Silver Corp. (TSX / NYSE American: MAG) (“MAG” or the […]
Norwegian Cruise Line Holdings Ltd. Announces Extension of Voluntary Suspension of Voyages
Extended Suspension Includes Voyages for Norwegian Cruise Line, Oceania Cruises and Regent Seven Seas Cruises with Embarkation Dates from April […]
CNH Industrial announces updates to COVID-19 emergency and its global business conditions
London, March 30, 2020Since the beginning of the COVID-19 pandemic outbreak, CNH Industrial (NYSE: CNHI / MI: CNHI) has been […]
TSX News -
The North West Company Inc. Provides an Update on COVID-19 Response, Posts Investor Information on Website
WINNIPEG, Manitoba, March 30, 2020 (GLOBE NEWSWIRE) — (TSX: NWC)Bay Street News
Wealth Minerals – Annual Filings Update
VANCOUVER, British Columbia, March 30, 2020 (GLOBE NEWSWIRE) — Wealth Minerals Ltd. (the “Company” or “Wealth”) – (TSXV: WML; OTCQX: […]
Aileron Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results
Phase 1b/2 clinical trial of ALRN-6924 as a myelopreservation agent for the protection against chemotherapy-induced toxicity in small cell lung […]
U.S. Energy Corp. Announces Full Year 2019 Financial and Operating Results
HOUSTON, March 30, 2020 (GLOBE NEWSWIRE) — U.S. Energy Corp. (NASDAQCM: USEG) (“We”, “U.S. Energy” or the “Company”) today announced […]
CytomX Therapeutics Announces Milestone Achievement in AbbVie CD71 Partnership and Provides Update on Impact of COVID-19 on Clinical Stage Pipeline
Achievement of Phase 1 Dose Escalation Criteria in AbbVie Partnership on CX-2029, a CD71-Directed Probody® Drug Conjugate, Triggers $40 Million […]
